These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34250949)

  • 1. Asymmetry at Disease Onset Is Not a Predictor of Parkinson's Disease Progression.
    Cotogni M; Sacchi L; Sadikov A; Georgiev D
    J Parkinsons Dis; 2021; 11(4):1689-1694. PubMed ID: 34250949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study.
    Koros C; Simitsi AM; Prentakis A; Papagiannakis N; Bougea A; Pachi I; Papadimitriou D; Beratis I; Papageorgiou SG; Stamelou M; Trapali XG; Stefanis L
    Parkinsonism Relat Disord; 2020 Aug; 77():36-42. PubMed ID: 32615498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Fiorenzato E; Antonini A; Bisiacchi P; Weis L; Biundo R
    Mov Disord; 2021 Oct; 36(10):2303-2313. PubMed ID: 34124799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderating effects of uric acid and sex on cognition and psychiatric symptoms in asymmetric Parkinson's disease.
    Constantin IM; Voruz P; Péron JA
    Biol Sex Differ; 2023 May; 14(1):26. PubMed ID: 37143121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology.
    Boertien JM; van der Zee S; Chrysou A; Gerritsen MJJ; Jansonius NM; Spikman JM; van Laar T;
    BMC Neurol; 2020 Jun; 20(1):245. PubMed ID: 32534583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor asymmetry over time in Parkinson's disease.
    Miller-Patterson C; Buesa R; McLaughlin N; Jones R; Akbar U; Friedman JH
    J Neurol Sci; 2018 Oct; 393():14-17. PubMed ID: 30096567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
    Brumm MC; Siderowf A; Simuni T; Burghardt E; Choi SH; Caspell-Garcia C; Chahine LM; Mollenhauer B; Foroud T; Galasko D; Merchant K; Arnedo V; Hutten SJ; O'Grady AN; Poston KL; Tanner CM; Weintraub D; Kieburtz K; Marek K; Coffey CS;
    J Parkinsons Dis; 2023; 13(6):899-916. PubMed ID: 37458046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson's disease.
    Béreau M; Castrioto A; Servant M; Lhommée E; Desmarets M; Bichon A; Pélissier P; Schmitt E; Klinger H; Longato N; Phillipps C; Wirth T; Fraix V; Benatru I; Durif F; Azulay JP; Moro E; Broussolle E; Thobois S; Tranchant C; Krack P; Anheim M
    Sci Rep; 2023 Dec; 13(1):21234. PubMed ID: 38040775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
    Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan Parkinson's Progression Markers Initiative (J-PPMI).
    Mukai Y; Murata M
    Nihon Rinsho; 2017 Jan; 75(1):151-155. PubMed ID: 30566310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial changes of I-123 FP-CIT SPECT binding asymmetry in Parkinson's disease: Analysis of the PPMI data.
    Jeong EH; Sunwoo MK; Lee JY; Han SK; Hyung SW; Song YS
    Front Neurol; 2022; 13():976101. PubMed ID: 36119683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.
    Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM; Chen-Plotkin AS
    Mov Disord; 2015 Oct; 30(12):1648-56. PubMed ID: 26207725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of Rapid symptoms progression in patients with newly diagnosed parkinson's disease.
    Tsiouris KM; Konitsiotis S; Koutsouris DD; Fotiadis DI
    Artif Intell Med; 2020 Mar; 103():101807. PubMed ID: 32143804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?
    Gerasimou G; Costa DC; Papanastasiou E; Bostanjiopoulou S; Arnaoutoglou M; Moralidis E; Aggelopoulou T; Gotzamani-Psarrakou A
    Ann Nucl Med; 2012 May; 26(4):337-44. PubMed ID: 22382608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.